Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy

Benjamin Piura, Ilana Yanai-Inbar, Alex Rabinovich, Svetlana Zalmanov, Jed Goldstein

    Research output: Contribution to journalArticlepeer-review

    62 Scopus citations

    Abstract

    Metastases to the female genital tract from extragenital cancers are uncommon. The ovaries are most often affected with the breast and gastrointestinal tract being the most common sites of the primary malignancy. Metastases to the uterus from extragenital cancers are significantly rarer than metastases to the ovaries and in the majority of cases the ovaries are also involved. A case of metastases restricted to the uterine corpus, cervix and vagina from breast carcinoma, without involvement of the ovaries, is described. The patient who had been on tamoxifen therapy presented with postmenopausal bleeding. The diagnosis of uterine metastases was established during endometrial ablation and confirmed by total abdominal hysterectomy and bilateral salpingo-oophorectomy. This case illustrates that abnormal uterine bleeding in a breast cancer patient, regardless of whether she is receiving or not receiving tamoxifen, should always alert the physician to consider the possibility of uterine metastases from breast carcinoma. Copyright (C) 1999 Elsevier Science Ireland Ltd.

    Original languageEnglish
    Pages (from-to)57-61
    Number of pages5
    JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
    Volume83
    Issue number1
    DOIs
    StatePublished - 1 Mar 1999

    Keywords

    • Abnormal uterine bleeding
    • Breast carcinoma
    • Postmenopausal bleeding
    • Tamoxifen
    • Uterine metastases

    ASJC Scopus subject areas

    • Reproductive Medicine
    • Obstetrics and Gynecology

    Fingerprint

    Dive into the research topics of 'Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy'. Together they form a unique fingerprint.

    Cite this